Delving into the Latest Updates on Lipegfilgrastim with Synapse

Overview

Basic Info

Drug Type

Colony-stimulating factors

Synonyms

GlycoPEG-GCSF, GlycoPEGylated G-CSF, GlycoPEGylated granulocyte colony-stimulating factor

+ [7]

Target

CSF-3R

Mechanism

CSF-3R agonists(Colony stimulating factor 3 receptor agonists)

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication

Febrile NeutropeniaNeutropenia

Inactive Indication

Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcoma

Originator Organization

Teva Pharmaceutical Industries Ltd.

Active Organization

Teva Pharmaceuticals Europe BVTeva-Handok Pharma Co., Ltd.

Inactive Organization

Merckle GmbH

Drug Highest PhaseApproved

First Approval Date

EU (25 Jul 2013),

Febrile NeutropeniaNeutropenia

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 4190

Source: *****

The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells for autologous stem cell transplantation in patients with lymphoma and multiple myeloma.

Start Date01 Jul 2017

Sponsor / Collaborator

Sheba Medical Center

EUCTR2015-000087-34-CZ / Not yet recruitingPhase 2

An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 µg/kg Body Weight in Comparison to Filgrastim 5 µg/kg Body Weight in Pediatric Patients Diagnosed with Ewing Family of Tumors or Rhabdomyosarcoma Receiving Chemotherapy

Start Date02 Jul 2015

Sponsor / Collaborator

Merckle GmbH

100 Clinical Results associated with Lipegfilgrastim

Login to view more data

100 Translational Medicine associated with Lipegfilgrastim

Login to view more data

100 Patents (Medical) associated with Lipegfilgrastim

Login to view more data

65

Literatures (Medical) associated with Lipegfilgrastim

01 Nov 2023·Clinical Lymphoma Myeloma and Leukemia

Loss of CD34+ Cells and Effect of the Number of Viable Cryopreserved CD34+ Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation

Article

Author: Penttilä, Karri ; Jantunen, Esa ; Valtola, Jaakko ; Kuittinen, Outi ; Kuitunen, Hanne ; Mäntymaa, Pentti ; Partanen, Anu ; Pyörälä, Marja ; Vasala, Kaija ; Turunen, Antti ; Kuittinen, Taru ; Varmavuo, Ville ; Pelkonen, Jukka

PATIENTSThis post-hoc study aimed to find out factors affecting graft viable CD34⁺ cell loss during processing and cryopreservation in 129 non-Hodgkin lymphoma (NHL) patients receiving autologous stem cell transplantation (auto-SCT) and the impact of a low (< 2.0 × 10⁶/kg, group A) and a decent number (≥ 2 × 10⁶/kg, group B) of viable CD34⁺ cells infused on the hematologic recovery, progression-free survival (PFS) and overall survival (OS) after auto-SCT.RESULTSThe median loss of viable CD34⁺ cells during cryopreservation was higher in group A (47% vs. 19%, p < .001). A higher yield of CD34⁺ cells at the first apheresis in group B (p = .002) was linked with greater loss of viable graft CD34⁺ cells after cryopreservation. Filgrastim (FIL) use for mobilization seemed to associate with higher viable CD34⁺ cell loss compared to pegfilgrastim (PEG) or lipegfilgrastim (LIPEG) in both groups (in group A FIL 66 vs. PEG 35%, p = .006; in group B FIL 37 vs. PEG 15 vs. LIPEG 13%, p < .001). Hematologic recovery after auto-SCT was faster in group B. Neither viable CD34⁺ cell loss during storage nor viable CD34⁺ cell number < 2.0 × 10⁶/kg infused affected on PFS or OS.CONCLUSIONSG-CSF type used in mobilization and mobilization capacity were found to correlate with viable CD34⁺ cell loss during processing and storage. Most importantly, low infused viable CD34⁺ cell count did not seem to impact on PFS or OS.

19 Jul 2023·Cancers

Assessing the Optimal Regimen: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Long-Acting Granulocyte Colony-Stimulating Factors in Patients with Breast Cancer.

Review

Author: Huang, Yining ; Zhao, Lei ; Zhang, Yuzhuo ; Tu, Hengjia ; Liang, Wenhua ; Zhang, Haotian ; Lin, Xinqing ; You, Zhixuan

Patients with breast cancer undergoing chemotherapy are susceptible to prolonged and severe neutropenia. Multiple biosimilars of long-acting granulocyte colony-stimulating factors (LA-G-CSFs) have been newly developed to prevent this disease. Nonetheless, which LA-G-CSF regimen has the optimal balance of efficacy and safety remains controversial. Moreover, there is a lack of evidence supporting clinical decisions on LA-G-CSF dose escalation in poor conditions. PubMed, Embase, Cochrane Library, Web of Science, and several Chinese databases were searched (December 2022) to collect randomized controlled trials (RCTs) about LA-G-CSFs preventing chemotherapy-induced neutropenia in breast cancer patients. No restrictions were imposed on language. A Bayesian network meta-analysis was performed. We assessed the incidence of severe neutropenia (SN) and febrile neutropenia (FN), the duration of SN (DSN), and the absolute neutrophil account recovery time (ANCrt) for efficacy, while the incidence of severe adverse events (SAE) was assessed for safety. The study was registered in PROSPERO (CRD42022361606). A total of 33 RCTs were included. Our network meta-analysis demonstrated that lipegfilgrastim 6 mg and eflapegrastim 13.2 mg outperformed other LA-G-CSFs with high efficacy rates and few safety concerns (SUCRA of lipegfilgrastim 6 mg: ANC rt 95.2%, FN 97.4%; eflapegrastim 13.2 mg: FN 87%, SN 89.3%). Additionally, 3.6 mg, 4.5 mg, 6 mg, and 13.2 mg dosages all performed significantly better than 1.8 mg in reducing the duration of SN (3.6 mg: DSN, SMD -0.68 [-1.13, -0.22; moderate]; 4.5 mg: -0.87 [-1.57, -0.17; low]; 6 mg: -0.89 [-1.49, -0.29; moderate]; 13.2 mg: -1.02 [1.63, -0.41; high]). Increasing the dosage from the guideline-recommended 6 mg to 13.2 mg can reduce both the duration and incidence of SN (SMD -0.13 [-0.24 to -0.03], RR 0.65 [0.43 to 0.96], respectively), with no significant difference in SAE. For patients with breast cancer, lipegfilgrastim 6 mg and eflapegrastim 13.2 mg might be the most effective regimen among LA-G-CSFs. Higher doses of LA-G-CSF may enhance efficacy without causing additional SAEs.

01 Jan 2023·Cancer Control

Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study

Article

Author: Ma, Peizhi ; Wang, Yaqin ; Zhao, Chenglong ; Jiang, Dandan

Purpose This retrospective analysis aimed to evaluate the clinical outcomes and cost-effectiveness of long-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia caused by chemotherapy for breast cancer. Methods Patients with breast cancer who received long- or short-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia were enrolled in this study, and incidences of neutropenia were compared between two groups. A decision-analytic and a Markov model were used to compare the health benefits and costs of utilizing long- vs short-acting granulocyte-colony stimulating factor as the primary prophylaxis from the perspective of the Chinese health service system. Subsequently, one-way deterministic and probabilistic sensitivity analyses were conducted. The incremental cost-effectiveness ratios were calculated in baseline and sensitivity analyses. Results Patients receiving long-acting granulocyte-colony stimulating factor as the primary prophylaxis of chemotherapy-induced neutropenia experienced a significant lower incidence of this adverse event, compared with the short-acting one for 2 to 7 days. The outcomes of baseline analysis indicated that long-acting granulocyte-colony stimulating factor had a gain of 0.08 quality-adjusted life years and costed $149 more than the short-acting one, yielding an incremental cost-effectiveness ratio of $1792 per quality-adjusted life year. The sensitivity analysis proved the stability of our models and economic efficiency of long-acting granulocyte-colony stimulating factor. Conclusions Patients receiving long-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia experienced lower risk of this event compared with those underusing short-acting one. The long-acting granulocyte-colony stimulating factor may be a more cost-effective strategy for primary prophylaxis of neutropenia than short-acting one, considering the Chinese willingness-to-pay threshold of $12158.6 per quality-adjusted life year.

100 Deals associated with Lipegfilgrastim

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10242	Lipegfilgrastim	L03AA14	DB13200

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Febrile Neutropenia	LI	Teva Pharmaceuticals Europe BV	25 Jul 2013
Febrile Neutropenia	IS	Teva Pharmaceuticals Europe BV	25 Jul 2013
Febrile Neutropenia	EU	Teva Pharmaceuticals Europe BV	25 Jul 2013
Febrile Neutropenia	NO	Teva Pharmaceuticals Europe BV	25 Jul 2013
Neutropenia	LI	Teva Pharmaceuticals Europe BV	25 Jul 2013
Neutropenia	IS	Teva Pharmaceuticals Europe BV	25 Jul 2013
Neutropenia	NO	Teva Pharmaceuticals Europe BV	25 Jul 2013
Neutropenia	EU	Teva Pharmaceuticals Europe BV	25 Jul 2013

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peripheral Primitive Neuroectodermal Tumors	Phase 1	RU	Merckle GmbH	01 Jul 2012
Peripheral Primitive Neuroectodermal Tumors	Phase 1	PL	Merckle GmbH	01 Jul 2012
Peripheral Primitive Neuroectodermal Tumors	Phase 1	UA	Merckle GmbH	01 Jul 2012
Rhabdomyosarcoma	Phase 1	CZ	Merckle GmbH	01 Jul 2012
Rhabdomyosarcoma	Phase 1	UA	Merckle GmbH	01 Jul 2012
Rhabdomyosarcoma	Phase 1	PL	Merckle GmbH	01 Jul 2012
Rhabdomyosarcoma	Phase 1	HU	Merckle GmbH	01 Jul 2012
Rhabdomyosarcoma	Phase 1	BG	Merckle GmbH	01 Jul 2012
Rhabdomyosarcoma	Phase 1	RU	Merckle GmbH	01 Jul 2012
Peripheral Primitive Neuroectodermal Tumors	Discovery	BG	Merckle GmbH	01 Jul 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


GOA (EBMT2020)	Not Applicable	Non-Hodgkin Lymphoma	104	Pegfilgrastim 6 mg	hglpxeyxlg(yvavezdbuq) = yzhdskpfkw kztbrcppoq (rmeuhzswzt ) View more	-	29 Aug 2020
GOA (EBMT2020)	Not Applicable	Non-Hodgkin Lymphoma	104	Lipegfilgrastim 6 mg	hglpxeyxlg(yvavezdbuq) = geossnxeue kztbrcppoq (rmeuhzswzt ) View more	-	29 Aug 2020
NADENS (ESMO2019)	Not Applicable	Breast Cancer	328	Lipegfilgrastim	(zmaxitzwte) = hyxetrzdut spoovqsjsx (pfnrgwxcsu ) View more	-	28 Sep 2019
NCT02488382 (EHA2019)	Phase 1/2	Multiple Myeloma	24	Lonquex	(ynnqqphdrn) = 13% hsgtpydhig (ohnmtgluyn ) View more	-	15 Jun 2019
ESMO2018	Not Applicable	Chemotherapy-Induced Febrile Neutropenia	-	Lipegfilgrastim	(gfqvmwkyjr) = hxgfebtxpo vubjrcwctd (bpqrureuvd ) View more	Positive	22 Oct 2018
EHA2017	Not Applicable	Lymphoma	249	Lipegfilgrastim	(zkmojgzqft) = bdgzfarymu lvikmmzycf (hsmvpqatta ) View more	Positive	18 May 2017
NCT01585649 (Pubmed \| Cancer Chemother Pharmacol) Manual	Phase 1	Peripheral Primitive Neuroectodermal Tumors \| Rhabdomyosarcoma	21	chemotherapy+lipegfilgrastim	(tbpgagyllw) = 57% of patients; febrile neutropenia, leukopenia, neutropenia, and thrombocytopenia dkcdbzbrtf (nxgzgteuhi )	Positive	01 Jan 2017
ASCO2015	Not Applicable	Febrile Neutropenia	53	Pegfilgrastim	(pzsnxdhxdk) = rffqadzssk spzdahuvcg (mbgkzwlylr ) View more	-	20 May 2015
ASCO2015	Not Applicable	Febrile Neutropenia	53	Lipegfilgrastim	(pzsnxdhxdk) = eyqhcelhbl spzdahuvcg (mbgkzwlylr ) View more	-	20 May 2015
ASCO2012	Not Applicable	Breast Cancer	-	Lipegfilgrastim 6 mg	(spiamgnyqz) = akkkngvauu oihffzsvvq (qbwsqiqmpw ) View more	Positive	20 May 2012
ASCO2012	Not Applicable	Breast Cancer	-	Pegfilgrastim 6 mg	(spiamgnyqz) = iqzddzsmad oihffzsvvq (qbwsqiqmpw ) View more	Positive	20 May 2012
XM22-02-INT (ASCO2011)	Not Applicable	Breast Cancer	208	XM22 3mg	(gdlqfzqsit) = sebakhaaon zbjucqeyqj (tqqmnljdpc )	Positive	20 May 2011
XM22-02-INT (ASCO2011)	Not Applicable	Breast Cancer	208	XM22 4.5mg	(gdlqfzqsit) = oxzaptyhew zbjucqeyqj (tqqmnljdpc )	Positive	20 May 2011